Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …

Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …

We performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA)
using paired tumor and adjacent liver tissues from 262 patients. Integrated proteogenomic …

Even though the immuno-oncology (IO) era has achieved many successes, some signs of
research development deceleration are arising. Recently, the number of FDA …

Immune checkpoint blockade (ICB) can produce durable responses against cancer. We and
others have found that a subset of patients experiences paradoxical rapid cancer …

The treatment landscape of driver-negative non-small-cell lung cancer (NSCLC) is rapidly
evolving. Immune-checkpoint inhibitors, specifically those targeting PD-1 or PD-L1, have …

Several tumour types are responsive to immunotherapy, as shown by regulatory approvals
for immune checkpoint inhibitors. However, many patients either do not respond or do not …

Targeting the interaction between tumor suppressor p53 and the E3 ligase MDM2
represents an attractive treatment approach for cancers with wild-type or functional TP53 …

The development of combination immunotherapy based on the mediation of regulatory
mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep …

Rationale: Siglec15 is an emerging target for normalization cancer immunotherapy.
However, pan-cancer anti-Siglec15 treatment is not yet validated and the potential role of …